REG - AOTI, Inc. - Notice of Results

AotiAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250908:nRSH3794Ya&default-theme=true

RNS Number : 3794Y  AOTI, Inc.  08 September 2025

8 September 2025

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

Notice of Results

 

AOTI, INC. (AIM: AOTI), a medical technology group focused on the durable
healing of wounds and the prevention of amputations, announces that it will
be releasing its interim results for the six months ended 30 June 2025 on
Monday 22 September 2025.

 

Analyst Meeting

A meeting for analysts will be held at 09:30 British Summer Time (BST) on
Monday 22 September, at the offices of FTI Consulting, 200 Aldersgate,
Aldersgate Street, London, EC1A 4HD. The presentation will also be held via
webcast. To register to attend in person or virtually, contact
AOTI@fticonsulting.com (mailto:AOTI@fticonsulting.com)

 

A recording of the webcast will be made available on AOTI's website following
the conclusion of the meeting at
https://aotinc.net/investors/financial-reports-publications-2/
(https://aotinc.net/investors/financial-reports-publications-2/)

 

Investor Presentation

A presentation for all existing and potential shareholders will be held via
the Investor Meet Company platform at 11:30 BST on Monday 22 September.

 

Questions can be submitted pre-event via your Investor Meet Company dashboard
up until 21 September, 09:00 BST, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet AOTI,
INC. via:

https://www.investormeetcompany.com/aoti-inc/register-investor
(https://www.investormeetcompany.com/aoti-inc/register-investor)

 

Investors who already follow AOTI, INC. on the Investor Meet Company platform
will automatically be invited.

 

ENDS

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer   +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer     ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Broker)

 Dr. Christopher Golden, James Steel           +44 (0)20 7418 8900

 FTI Consulting (Financial PR & IR)

 Ben Atwell, Simon Conway,                     +44 (0)20 3727 1000

 Natalie Garland-Collins                       AOTI@fticonsulting.com (mailto:AOTI@fticonsulting.com)

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomized controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalizations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA),
Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical
Products Administration, Australia (TGA) and in Saudi Arabia.
TWO(2)(®) therapy has also recently received positive recommendation from
the Federal Joint Committee of Gemeinsamer Bundesausschuss (G-BA) in Germany
and National Institute for Health and Care Excellence (NICE) in the United
Kingdom. Also see www.aotinc.net (http://www.aotinc.net/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKZGGLGNFGKZZ